PDIA3 - Protein Disulfide Isomerase Family A Member 3

title: PDIA3 - Protein Disulfide Isomerase Family A Member 3
category: gene

PDIA3 — Protein Disulfide Isomerase Family A Member 3

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Protein Disulfide Isomerase Family A Member 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>PDIA3</td></tr>
<tr><td><strong>Full Name</strong></td><td>Protein Disulfide Isomerase Family A Member 3</td></tr>
<tr><td><strong>Chromosome</strong></td><td>15q15.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[10195](https://www.ncbi.nlm.nih.gov/gene/10195)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[604046](https://www.omim.org/entry/604046)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000167077</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P27773](https://www.uniprot.org/uniprot/P27773)</td></tr>
<tr><td><strong>Protein Aliases</strong></td><td>ERp57, GRP58</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Cancer</td></tr>
</table>
</div>

Pathway / Interaction Diagram

Overview

title: PDIA3 - Protein Disulfide Isomerase Family A Member 3
category: gene

PDIA3 — Protein Disulfide Isomerase Family A Member 3

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Protein Disulfide Isomerase Family A Member 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>PDIA3</td></tr>
<tr><td><strong>Full Name</strong></td><td>Protein Disulfide Isomerase Family A Member 3</td></tr>
<tr><td><strong>Chromosome</strong></td><td>15q15.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[10195](https://www.ncbi.nlm.nih.gov/gene/10195)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[604046](https://www.omim.org/entry/604046)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000167077</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P27773](https://www.uniprot.org/uniprot/P27773)</td></tr>
<tr><td><strong>Protein Aliases</strong></td><td>ERp57, GRP58</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Cancer</td></tr>
</table>
</div>

Pathway / Interaction Diagram

Overview

PDIA3 (Protein Disulfide Isomerase Family A Member 3), also known as ERp57 (Endoplasmic Reticulum Protein 57) or GRP58 (Glucose-Regulated Protein 58), is a multifunctional endoplasmic reticulum (ER)-resident protein that plays critical roles in protein folding, redox homeostasis, calcium signaling, and cellular stress responses. As a member of the protein disulfide isomerase (PDI) family, PDIA3 catalyzes the formation, reduction, and rearrangement of disulfide bonds in nascent polypeptides, ensuring proper protein tertiary and quaternary structure within the oxidizing environment of the ER.[@turano2002] Beyond its canonical enzymatic function, PDIA3 serves as a molecular chaperone, facilitates ER-associated degradation (ERAD), participates in calcium homeostasis, and can translocate to the cell surface where it has distinct functions in cell adhesion and signaling.

Recent research has implicated PDIA3 prominently in the pathogenesis of neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), where it helps manage protein folding stress and interacts with disease-relevant proteins including amyloid precursor protein (APP), amyloid-beta (Aβ), and alpha-synuclein (SNCA).[@honda2017] The protein's elevated expression in AD brain, its interaction with key disease proteins, and its central position in the ER stress response make it an important player in neurodegeneration research. Genetic variants in PDIA3 have been associated with increased risk for neurodegenerative diseases, further supporting its biological relevance. The multifunctional nature of PDIA3—combining enzymatic activity, chaperone function, and signaling roles—creates a complex relationship with disease processes that continues to be elucidated through basic and translational research.

Molecular Biology and Structure

The PDIA3 gene is located on chromosome 15q15.3 and encodes a protein of 505 amino acids with a molecular weight of approximately 57 kDa, explaining its original designation as ERp57. The protein structure consists of multiple functional domains that confer its diverse capabilities. The N-terminal region contains a thioredoxin-like domain (domain A), followed by a linker region, a second thioredoxin-like domain (domain B), and a C-terminal acidic domain. This modular architecture is shared with other PDI family members and enables PDIA3 to catalyze disulfide bond formation while also binding client proteins through distinct surfaces.

The two thioredoxin-like domains (A and B) each contain the canonical CXXS motif that defines the active site for disulfide bond formation. Domain A (residues 22-167) contains the CGHC active site sequence and is the primary catalytic domain, while domain B (residues 226-341) has the CGHC motif and contributes to substrate recognition and binding. The thioredoxin-like folds create a structure reminiscent of other oxidoreductases, with βαβαββα fold topology providing the catalytic surface. The C-terminal domain (residues 342-505) is less structured and contains multiple acidic residues that may be involved in calcium binding or protein-protein interactions.

PDIA3 localizes primarily to the endoplasmic reticulum, where it performs its canonical functions in protein folding. ER retention is mediated by the KDEL sequence (Lys-Asp-Glu-Leu) at the C-terminus, which interacts with KDEL receptors in the ER membrane and retrieves the protein from the Golgi. However, PDIA3 can also be found at the cell surface and in extracellular spaces under certain conditions, where it has distinct functions in cell adhesion and signaling. Additionally, PDIA3 has been detected in the nucleus, where it may participate in DNA damage responses or other nuclear functions.

The expression of PDIA3 is regulated at multiple levels. Transcriptional regulation involves the unfolded protein response (UPR), a collection of signaling pathways activated by ER stress. PDIA3 is an ER stress-inducible gene, with its promoter containing response elements that bind XBP1 and other UPR transcription factors. This induction is part of the adaptive response to ER stress and helps increase the protein folding capacity of the ER. Post-translational modifications including glycosylation and phosphorylation further regulate PDIA3 activity and localization.

Functions in Protein Folding and Redox Homeostasis

PDIA3's primary cellular function is catalyzing disulfide bond formation in the endoplasmic reticulum. Disulfide bonds are covalent linkages between cysteine residues that stabilize protein tertiary and quaternary structures. In the oxidizing environment of the ER, PDIA3 facilitates the proper formation of these bonds through its thiol-disulfide oxidoreductase activity. The catalytic cycle involves reduction of the active site disulfides, followed by nucleophilic attack on substrate cysteine residues, forming a mixed disulfide intermediate. Resolution of this intermediate transfers the disulfide to the substrate, properly oxidizing it.

The substrate specificity of PDIA3 is broad, encompassing numerous ER-resident proteins and secretory proteins. PDIA3 works in concert with other PDI family members and ER oxidoreductases to ensure proper protein folding. Its ability to recognize and bind misfolded proteins contributes to its chaperone function—when proteins fail to achieve proper conformation, PDIA3 can bind to them and either facilitate proper folding or target them for degradation through ERAD. The balance between productive folding and degradation determines whether stressed cells can recover or undergo apoptosis.

Beyond disulfide bond formation, PDIA3 participates in redox regulation through its ability to reduce as well as oxidize disulfide bonds. This reversibility allows PDIA3 to isomerase disulfide bonds, rearranging incorrect linkages to achieve proper folding. The dual oxidase/reductase activity is a hallmark of PDI family members and distinguishes them from simple oxidases. PDIA3 can also reduce glutathione and other low molecular weight thiols, contributing to the overall redox environment of the ER.

The ER redox environment is distinct from the cytosol, with a higher oxidized state that favors disulfide bond formation. PDIA3 contributes to maintaining this environment through its catalytic activity and through interactions with other ER proteins including Ero1α and ERp44, which help regenerate the oxidized state of PDI family members. Disruption of ER redox balance occurs in various disease states and contributes to protein misfolding and stress.

Role in ER-Associated Degradation (ERAD)

ER-associated degradation (ERAD) is a quality control pathway that targets misfolded proteins in the endoplasmic reticulum for ubiquitination and degradation by the proteasome. PDIA3 participates in ERAD by recognizing misfolded proteins and facilitating their retrotranslocation from the ER to the cytosol. This function requires PDIA3 to interact with other ERAD components including selenoprotein K (SELK), Derlin proteins, and the AAA ATPase p97.

In the ERAD pathway, PDIA3 can recognize substrates through its chaperone activity, binding to misfolded proteins and potentially facilitating their extraction from the ER membrane or lumen. The substrate recognition involves recognition of hydrophobic patches or other structural features that indicate misfolding. Once recognized, PDIA3 can hand off substrates to the retrotranslocation machinery, which translocates proteins across the ER membrane into the cytosol where they are ubiquitinated and degraded.

The importance of PDIA3 in ERAD has implications for neurodegenerative diseases, where protein aggregation is a common feature. In conditions like AD and PD, the capacity of the ERAD system may be overwhelmed, leading to accumulation of misfolded proteins. Enhancing ERAD function through PDIA3 upregulation or modulation has been proposed as a therapeutic strategy, though the complexity of the pathway creates challenges for intervention.

Calcium Homeostasis and Signaling

PDIA3 participates in calcium homeostasis through its calcium-binding capacity and interactions with calcium channels and buffers. The C-terminal domain of PDIA3 contains acidic residues that can bind calcium, potentially acting as a calcium buffer. More importantly, PDIA3 interacts with the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and other calcium-handling proteins, influencing calcium dynamics in cells.

In neurons and other cell types, calcium signaling is essential for numerous functions including synaptic transmission, gene expression, and cell survival. Dysregulation of calcium homeostasis is implicated in neurodegenerative diseases, and PDIA3's role in this process contributes to its disease relevance. ER calcium stores are particularly important for cellular signaling, and PDIA3 helps maintain proper calcium handling.

Stress responses involving calcium are also modulated by PDIA3. In response to various cellular stresses, calcium is released from ER stores, triggering downstream signaling cascades. PDIA3 may help buffer these calcium fluctuations or participate in the signaling events triggered by calcium release. The relationship between PDIA3 and calcium is bidirectional—calcium depletion from the ER induces ER stress and activates the UPR, which in turn upregulates PDIA3.

Interactions with Disease-Relevant Proteins

In Alzheimer's disease, PDIA3 interacts with amyloid precursor protein (APP) and influences amyloid-beta production. Studies have demonstrated physical interactions between PDIA3 and APP in cellular and animal models. This interaction may affect APP processing by altering its folding, trafficking, or interaction with secretases. PDIA3 expression is elevated in AD brain, and this upregulation may represent a response to increased protein folding stress or a direct effect of Aβ on PDIA3 expression.

PDIA3 also interacts directly with Aβ peptides. Both monomeric and oligomeric Aβ can bind to PDIA3, potentially affecting its enzymatic activity and chaperone function. The interaction may influence Aβ aggregation—PDIA3 could potentially facilitate Aβ clearance or alternatively be co-opted by Aβ into toxic aggregates. Some studies suggest PDIA3 may help protect against Aβ-induced toxicity, while others indicate that Aβ can impair PDIA3 function, creating a pathogenic cycle.

In Parkinson's disease, PDIA3 interacts with alpha-synuclein, the protein that forms Lewy bodies in affected neurons. Physical interactions between PDIA3 and α-synuclein have been documented, and PDIA3 may influence α-synuclein aggregation and clearance. The ER stress induced by α-synuclein aggregation would be expected to upregulate PDIA3, and some studies have demonstrated this response in cellular models. Conversely, PDIA3 may help manage the ER stress caused by α-synuclein, representing either a protective response or an insufficient attempt at compensation.

Additional disease-relevant interactions include those with tau protein in AD, parkin in PD, and various other proteins involved in protein quality control and cellular stress responses. The breadth of these interactions reflects PDIA3's central position in ER function and protein homeostasis.

Expression in the Brain

PDIA3 is widely expressed in all tissues, with particularly high expression in brain, liver, and pancreas—all tissues with high protein folding demands. In the brain, PDIA3 is expressed in neurons and glial cells across various regions including the hippocampus, cerebral cortex, and basal ganglia. This widespread expression supports PDIA3's fundamental role in cellular protein folding machinery.

Within neurons, PDIA3 is localized to the soma, dendrites, and synapses. Synaptic PDIA3 may participate in the folding of synaptic proteins, which have high turnover and require sophisticated quality control. The presence of PDIA3 at synapses also suggests potential functions in synaptic plasticity, where protein synthesis and folding are dynamically regulated.

Expression is dynamically regulated by cellular stress, particularly ER stress. The unfolded protein response activates PDIA3 transcription through transcription factors including XBP1 and ATF6. In neurodegenerative diseases, where ER stress is chronic, PDIA3 upregulation is a consistent finding. This stress-induced expression is both a marker of pathology and potentially a therapeutic target.

Glial expression of PDIA3 is also relevant to neurodegeneration. Astrocytes and microglia express PDIA3 and respond to ER stress with upregulation. In disease states, glial PDIA3 may contribute to inflammatory responses or help manage protein stress in the glial compartment.

Alzheimer's Disease

In Alzheimer's disease, PDIA3 has emerged as a significant player through multiple mechanisms. The protein is upregulated in AD brain, with increased expression detected in neurons, astrocytes, and microglia surrounding amyloid plaques. This upregulation likely reflects the ER stress induced by Aβ pathology and other disease mechanisms.

The interaction between PDIA3 and APP/Aβ has several implications. PDIA3 may help manage the folding stress caused by APP processing and Aβ production. However, chronic exposure to Aβ may overwhelm the protective capacity of PDIA3 and other ER quality control systems. The balance between PDIA3's protective functions and the pathological demands placed upon it may determine whether neurons survive or undergo apoptosis.

ER stress is a recognized feature of AD pathogenesis, and PDIA3's role in the unfolded protein response is directly relevant. The UPR is activated in AD brains, and the adaptive responses it triggers—including PDIA3 upregulation—are insufficient to prevent disease progression. Understanding the PDIA3 component of the UPR may provide insights into why the adaptive response fails and how it might be enhanced therapeutically.

Genetic associations between PDIA3 variants and AD risk have been reported, though the functional significance of these associations is not always clear. Some PDIA3 polymorphisms may be associated with altered expression or activity, potentially influencing disease risk or progression. This genetic evidence supports PDIA3's biological relevance beyond correlative expression studies.

Parkinson's Disease

In Parkinson's disease, PDIA3 involvement relates to alpha-synuclein pathology, ER stress, and dopaminergic neuron survival. The characteristic loss of dopaminergic neurons in the substantia nigra involves ER stress and protein folding challenges, creating demand for PDIA3 and other ER quality control proteins.

The interaction with α-synuclein has received particular attention. PDIA3 can bind to α-synuclein and may influence its aggregation kinetics. Some studies suggest PDIA3 may help prevent α-synuclein aggregation, while others indicate complex interactions that may have both protective and pathogenic aspects. The ER stress induced by α-synuclein aggregation would be expected to upregulate PDIA3, and this has been confirmed in cellular models.

Dopaminergic neurons may be particularly vulnerable to PDIA3 dysfunction due to their high protein folding demands and the specific stressors affecting them. The combination of mitochondrial dysfunction, oxidative stress, and protein aggregation creates multiple challenges that could stress the ER and require increased PDIA3 function.

PDIA3 genetic variants have been associated with PD risk in some populations, providing additional evidence for its relevance. The functional consequences of these variants are under investigation, with effects on expression levels, protein function, or splicing being considered.

Therapeutic Implications

PDIA3 represents a potential therapeutic target for neurodegenerative diseases through several mechanisms. Enhancing PDIA3 function or expression could improve protein folding capacity and help manage the folding stress that characterizes these diseases. Small molecules that upregulate PDIA3 or enhance its activity are being investigated as potential neuroprotective agents.

ER stress modulators that target the UPR represent another approach. Since PDIA3 is downstream of UPR activation, interventions that reduce ER stress or enhance UPR signaling could indirectly increase PDIA3 levels. However, the complexity of the UPR creates challenges—simply enhancing adaptive responses may not be sufficient if the underlying stressors persist.

Protein folding enhancers represent a more direct approach. Compounds that assist protein folding, stabilize native states, or prevent aggregation could reduce the demand on PDIA3 and other quality control systems. These approaches are being explored for various neurodegenerative diseases.

Biomarker applications for PDIA3 are also being developed. PDIA3 can be detected in cerebrospinal fluid, and its levels may correlate with disease state or progression. As a marker of ER stress and protein homeostasis status, PDIA3 could provide useful diagnostic or monitoring information.

Relationship with Other PDI Family Members

The PDI family includes multiple members (PDIA1/P4HB, PDIA2, PDIA3/ERp57, PDIA4/ERp72, PDIA5/P5, PDIA6/P5) that share structural features and functions but have distinct substrate specificities and expression patterns. Understanding PDIA3 in the context of this family provides important perspective on its specific roles.

PDIA1 (P4HB) is the most abundant PDI family member and catalyzes disulfide bond formation in most folding substrates. PDIA3 has more specialized functions, often working together with PDIA1 or acting on specific substrates. The cooperative relationships between PDI family members create redundancy and ensure robust protein folding capacity.

PDIA3 has unique features compared to other family members, including its ability to form complexes with calnexin and calreticulin—ER chaperones that work together with PDIA3 in folding certain glycoproteins. This specialization reflects PDIA3's distinct substrate preferences and regulatory mechanisms.

Other ER chaperones and stress response proteins interact with PDIA3, including BiP (HSPA5/GRP78), which is the major ER chaperone and a key player in the unfolded protein response. The coordination between these proteins ensures proper protein folding and helps manage ER stress.

Key Publications

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD disease page
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD disease page
• [alpha-Synuclein](/proteins/alpha-synuclein) — SNCA protein
• [ERp57 Protein](/proteins/pdia3-protein) — Related protein page
• [Unfolded Protein Response](/mechanisms/unfolded-protein-response) — UPR pathway
• [Protein Folding](/mechanisms/protein-folding-quality-control) — Protein folding mechanisms

External Links

• [NCBI Gene: 10195](https://www.ncbi.nlm.nih.gov/gene/10195) — Gene database entry
• [UniProt: P27773](https://www.uniprot.org/uniprot/P27773) — Protein sequence and structure
• [Ensembl: ENSG00000167077](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167077) — Genome browser
• [OMIM: 604046](https://www.omim.org/entry/604046) — Mendelian inheritance database

References

Pathway Diagram

The following diagram shows the key molecular relationships involving PDIA3 - Protein Disulfide Isomerase Family A Member 3 discovered through SciDEX knowledge graph analysis: